Pharma Emerging Markets: The New Gold Rush
eyeforpharma publish 60+ report on current and future healthcare expenditure, population fluctuations and optimum strategies for growth in BRICM countries.
- (1888PressRelease) September 15, 2011 - Over the next five years overall expenditure in healthcare across BRICM regions is set to be over $360 billion whilst the population being served within these countries is expected to increase from the currently 2.9 billion to 3.2 billion in 2021.
Government's willingness for investment in Pharma, combined with population increases must be utilized yet, undoubtedly is subject to a number of hurdles which must first be overcome. In Mexico, for instance, a more innovative approach to pricing needs to be conceptualised in order to be accessible to the populations means.
Addressing critical challenges to ensure maximum industry growth, leading players in the market have come together in eyeforpharma's latest report; Pharma Emerging Markets Report 2011-12. The report will enable readers to gain insights into emerging markets current and future healthcare expenditure, population fluctuations to determine optimum strategies for growth.
The comprehensive findings derive from both quantitative and qualitative methods to ensure reliability. The qualitative research involved over 200 hundred interviews with industry executives working within the emerging markets themselves for top pharma companies including; Mereck, Bayer and Janssen. We forecasted through the analysis of the previous 30 years top healthcare needs within BRICM countries and a report specially compiled by Global Demographics Healthcare from multiple sources combining health and epidemiology parameters with demographic and socioeconomic factors.
"As the world becomes ever more connected and the pace of change ever more vertiginous, successful companies are those that are not afraid to confess that they don't know it all, and are continuously pursuing and experimenting with new knowledge to maximize growth. In this context, the report from eyeforpharma on the BRICM markets is an excellent overview based on interviews with country experts offering a quick snapshot of the current state of the five countries' pharmaceutical markets, their growth opportunities and real life case studies providing marketing and sales insights to increasing the odds in succeeding in these fast growing emerging markets."
Former vice-president, Strategic Marketing, Latin America and Asia Pacific Johnson & Johnson. Currently consultant, AuPATH LLC.
The report is priced at €1195 and available for pre-order from 16th August 2011 at a €200 discount until the 9th of September. Thereafter early bird orders will receive a €100 discount until 6th October 2011.
Get further details and view exclusive selected findings at our website:
If you have any queries get in touch via the method below:
Research & Reports Director
T: +44 (0)20 375 7175
E: vstinson ( @ ) eyeforpharma dot com